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Tissue heterogeneity of EGFR gene mutation was studied in 10
formalin-fixed paraffin-embedded (FFPE) samples from four cases
that demonstrated EGFR mutations in snap-frozen samples. EGFR
mutations identical to those in frozen sample were demonstrated in
8 of 10 FFPE samples by direct sequencing and in 9 of 10 by
fragment length analysis, but an exon-19 deletion mutation could not
be identified in one FFPE sample analyzed by both techniques,
despite multiple repeated assays. This suggests that some tumors
may demonstrate intratumoral heterogeneity for the occurrence of
EGFR mutation.
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Mutation in the tyrosine kinase domain of the epidermalgrowth factor receptor (EGFR) gene is reported to
occur frequently in Asian patients with non-small cell lung
carcinoma, but less frequently in non-Asian patients.1 The
presence of mutation is highly correlated with response to
EGFR tyrosine kinase inhibitor (TKI) therapy,2,3 but avail-
able samples for mutational analysis are often limited to
small, formalin-fixed paraffin-embedded (FFPE) biopsy tis-
sue. In the recent studies performed on specimens from large
randomized clinical trials of EGFR TKIs, specimens that con-
tained sufficient tumor cells for study were available in only 24
to 28% of trial patients, and only 59 to 90% of the specimens
demonstrated informative results for sequencing.4–7 Thus, the
efficiency of mutation detection in FFPE is an important
limiting factor in these studies.
The possibility of tissue heterogeneity for the occur-
rence of EGFR mutation within tumors is potentially an
important consideration, as it might influence the results of
mutation screening. With small biopsy samples, tissue heter-
ogeneity may result in the analyzed sample being nonrepre-
sentative of the tumor, leading to misinterpretation of the
mutation results. Tissue heterogeneity for the occurrence of
p53 or KRAS mutations has been reported in many types of
tumors8–10; this issue for EGFR mutation in lung cancer has
not been addressed.
To check the genetic heterogeneity and detectability of
EGFR mutation on FFPE, we analyzed EGFR mutation on
different paraffin block samples from separate areas of the
same tumor that previously showed EGFR mutation by se-
quencing on fresh frozen specimens.
MATERIALS AND METHODS
The University Health Network Research Ethics Board
approved this study, which was conducted on four surgically
resected adenocarcinoma tumors that had been found previously
to harbor EGFR tyrosine kinase domain mutations upon analysis
of their fresh frozen tumor samples (Table 1). Two cases (case
P10 and P114) had L858R mutations, whereas the other two
(case P163 and P229) had 15-nucleotide deletions (del_E746-
A750) in exon-19. All patients were never smokers. Paraffin
blocks from these tumors were available for study. When mul-
tiple blocks were available, they were taken from different areas
of the same tumor (Table 1). The histology of the same tumor in
different blocks was not significantly different. Standard muta-
tion analysis on exon-19 and exon-21 of EGFR were performed
as described previously.6 Briefly, paraffin sections were scraped
off the slides for DNA extraction, and DNA was amplified by
the nested polymerase chain reaction (PCR). The PCR products
were sequenced with the ABI3100 sequence analyzer (Ap-
plied Biosystems, Foster City, CA). For blocks with less than
50% estimated tumor cell content, enrichment by microdis-
section was performed. For each block, three independent
PCR-sequencing reactions were performed.
The fragment length analysis (FLA) method of EGFR
mutation analysis was performed as previously reported by
Pan et al.11 The genomic sequences of exons-19 and -21 were
amplified using their respective forward primers and fluores-
cent-labeled reverse primers, and the PCR products were
analyzed by ABI 3100 (Applied Biosystems). The length of
the PCR products from exon-19 deletion mutants was eval-
uated with Genotypes Plot software (Applied Biosystems).
The 222-base pairs (bp) of PCR products on exon-21 were
treated with Sau39I, which digests wild-type sequence to
produce a 173-bp fluorescent-labeled fragment, whereas the
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mutant sequence produced an 87-bp fluorescently labeled
fragment due to the creation of a Sau39I restriction site by the
L858R mutation.
RESULTS
Mutations identical to those found in the frozen tumor
specimens were confirmed in 9 of 10 paraffin blocks. Three
independent repeats of PCR and sequencing assays failed
to detect the L858R mutation in paraffin block P114#1 or
the 15-nucleotide deletion of exon-19 in the P163#1 block
(Table 2).
Using the FLA method, L858R mutation was con-
firmed in all five paraffin blocks including P114#1 that was
negative by direct sequencing assay. In 4 of 5 paraffin
blocks from tumors P163 and P229, the exon-19 15-
nucleotide deletion was readily found. However, this de-
letion could not be identified in DNA isolated from the
P163#1 paraffin block, either by repeated direct sequenc-
ings or using FLA on DNA isolated independently from
serial paraffin sections (Figure 1).
DISCUSSION
We have provided evidence for the existence of intra-
tumoral heterogeneity for EGFR tyrosine kinase domain
mutations in lung adenocarcinoma. With the limited number
of cases studied, we only found such heterogeneity with the
exon-19 deletion. In the current study, P163#1 was negative
for deletion not only by direct sequencing but also by FLA.
Possible reasons why we did not detect the deletion from this
paraffin block include: low concentration of mutant se-
quences caused by high normal cell contamination, or intra-
tumoral heterogeneity for mutation occurrence. The first
possibility is unlikely because the H&E section showed more
than 50% population of tumor cells with a histologic appear-
ance identical to the other blocks positive for this deletion.
FIGURE 1. The histopathology, direct sequencing, and fragment length analysis results on three different paraffin blocks of
case P163. Left pictures show histology (H&E staining) of paraffin sections from blocks P163#1(A), #2(D), and #3(G). All sec-
tions showed similar morphology. Deletion was demonstrated in P163#2(E) and P163#3(H) as indicated by black arrows but
not in P163#1(B). The 15-nt deletion was also demonstrated by LFA in P163#2(F) and P163#3(I) as indicated by red arrows,
but not in P163#1(C).
TABLE 1. Patients Characteristics
Case
No. Gender Age Stage Histology
EGFR
Status
Paraffin
Blocks
Available
P10 Female 62 IB Well-differentiated
adenocarcinoma
L858R 2
P114 Female 42 IIIA Moderately
differentiated
adenocarcinoma
L858R 1
P163 Female 66 IB Well-differentiated
adenocarcinoma
Del_E746_A750 3
P229 Female 66 IB Well-differentiated
adenocarcinoma
Del_E746_A750 2
TABLE 2. Results of Direct Sequencing and Fragment
Length Analysis on the FFPE Samples
Case
No.
Mutation In
Frozen Tumor
Tissue
Paraffin
Block
No.
Direct
Sequencing
Analysis
Fragment
Length
Analysis
P10 L858R 1 L858R L858R
2 L858R L858R
P114 L858R 1 Wild type L858R
P163 Del_E746_A750 1 Wild type Wild-type
2 Del_E746_A750 15nt deletion
3 Del_E746_A750 15nt deletion
P229 Del_E746_A750 1 Del_E746_A750 15nt deletion
2 Del_E746_A750 15nt deletion
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Furthermore, we have independently confirmed that FLA is
sensitive enough to detect mutant alleles even at 100-fold
lower levels than concurrently present wild-type alleles, es-
pecially for deletion mutations (data not shown).11 Although
we cannot exclude other less obvious mechanisms, heteroge-
neity is the likely reason for our finding.
To the best of our knowledge, no similarly designed
studies to evaluate tumor heterogeneity of EGFRmutations have
been reported. Nagai et al.12 previously reported that among
non-small cell lung cancer cell lines screened, 11 demonstrated
EGFR mutations in 100% of cells whereas eight cell lines had
mutation in only 10% or less of the tumor cells. The latter results
are consistent with the presence of genetic heterogeneity or
instability of the mutations in these cell lines.
EGFR mutation status has been assessed in atypical
adenomatous hyperplasia, BAC, and invasive adenocarci-
noma in Japanese patients, and the frequencies of mutation
were reported to be 3%, 11%, and 42%, respectively.13 This
increasing frequency of EGFR mutation with histologic pro-
gression of malignancy has led to the hypothesis that atypical
adenomatous hyperplasia lesion with EGFR mutation prefer-
entially progress because of an mutation-induced growth
advantage. Mutation screening on normal bronchial epithe-
lium of patients with EGFR-mutant tumor has also revealed
the presence of identical EGFR mutations in 9 of 21 (43%) of
corresponding normal epithelial samples studied.14 The au-
thors speculated that this high frequency of mutations in
normal epithelium is caused by the “limited field effect.”
These results suggest that tumors with EGFR mutation ac-
quire the mutation early during carcinogenesis.
The finding of multiple EGFR mutations in a single
specimen has been reported in a number of studies.3,4,6
Multiple simultaneously detected EGFR mutations may sug-
gest the possibility of intratumoral heterogeneity and meta-
chronous generation of different mutations. Among those
multiple mutations, concurrent T790M mutation associated
with exon-19 deletions or L858R mutation appear to confer
acquired resistance to TKIs.15 However, such mutations have
been detected only at very low frequency, both in recurrent
and untreated tumors.15 Although the impact of multiple
mutations is not fully understood, it might indicate the insta-
bility of EGFR mutations. Nevertheless, based on the T790M
result, it is possible that the existence of even a minor
subpopulation of EGFR wild-type tumor cells in dominant
population of EGFR mutant tumor cells could impact on
response to TKIs. Therefore, although the frequency of in-
tratumoral heterogeneity appears low, this might become an
important issue when only very small biopsy specimens are
available for mutation analysis to direct therapy. The effect of
genetic heterogeneity on the response and prognosis with TKI
therapy warrants further studies.
Recently, there has been discussion on the sensitivity of
the direct sequencing method to detect EGFR mutations in
FFPE samples.16 Using this technique, we failed to detect the
original mutation/deletion in 2 of 10 blocks after at least three
independent PCR assays. However, one of these negative
cases yielded a positive result by a single FLA study, which
had been optimized to detect L858R or exon-19 deletion
mutations. This is consistent with the results of Pan et al.11 In
conclusion, we have identified intratumoral heterogeneity in
an adenocarcinoma with minor component of EGFR wild-
type tumor cells and a majority of tumor cells having exon-19
deletion mutation. The clinical significance of intratumoral
heterogeneity warrants future studies.
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